Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes

Summary

This 52-week multicenter open-labeled extension study is designed to assess the long-term safety of vildagliptin (100 mg qd) in patients with Type 2 Diabetes. This extension study is open to patients who have completed core study CLAF237A1303.

Timeline

Start

2006-10

Primary completion

—

Completion

—

Drugs

Indications